While treatment of metastatic PC has historically consisted of hormonal therapy with androgen deprivation, chemotherapy, and various radiotherapy approaches, the recent approval of PARPis, such as rucaparib and olaparib, has revolutionized the therapeutic algorithm of metastatic castration-resistant PC (mCRPC) and led to a marked improvement in clinical outcomes for patients with BRCA1/2 mutations [3,4,5,6,7]. This evidence concerns the gene BRCA1 and pachyonychia congenita.